Ultimately, investigators found a significant reduction in ischemic stroke risk with asundexian compared to placebo, both in combination with antiplatelet therapy. Additionally, participants had no ...

Leading Acute Ischemic Stroke companies are Acticor Biotech, DiaMedica Therapeutics, Lumosa Therapeutics, Bristol Myers ...

Tenecteplase shows no benefit over standard care for 90-day functional recovery in patients with minor ischemic stroke and disabling deficits.

Imperative Care, Inc. today announced the presentation of late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0, a next-generation approach to A ...

TAIPEI (Taiwan News) — Taiwan's Lumosa Therapeutics Co. announced Thursday that it has received written guidance from the US ...

Argenica Therapeutics has taken a step forward in the development of its neuroprotective drug candidate ARG-007 in acute ...

The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate ...

A research paper by scientists at the Capital Medical University evaluated sex differences in stroke recurrence among ...

Stroke and heart attack are life-threatening conditions that require emergency medical attention, but they differ in the affected organ and symptoms.

Systematic review suggests GLP-1 receptor agonists offer strong preclinical neuroprotection in nondiabetic ischemic stroke, ...

Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...

COVID-19 infection is associated with ischemic and hemorrhagic spinal stroke, with distinct clinical characteristics and underlying mechanisms.